Angiosarcoma in a soft tissue sarcoma cohort: real-world patterns and outcomes - Scorecard - MDSpire

Angiosarcoma in a soft tissue sarcoma cohort: real-world patterns and outcomes

  • By

  • Kübra Canaslan

  • Özge Yetginoğlu

  • Hasan Oğuz Çetinayak

  • Emine Burçin Tuna

  • Tuğba Yavuzşen

  • June 9, 2026

  • 0 min

Share

Clinical Scorecard: Angiosarcoma Among Patients with Soft Tissue Sarcomas: Observational Trends and Prognostic Outcomes

At a Glance

CategoryDetail
Condition
Key MechanismsAggressive vascular sarcoma arising from endothelial cells.
Target Population
Care Setting

Key Highlights

  • Angiosarcoma accounts for approximately 1-2% of all soft tissue sarcomas.
  • 75% of patients presented with metastatic/unresectable disease at diagnosis.
  • Median overall survival was 9.5 months; median progression-free survival was 4.8 months.

Guideline-Based Recommendations

Diagnosis

    Management

      Monitoring & Follow-up

        Risks

        • R
        • e
        • m
        • o
        • v
        • e
        • u
        • n
        • s
        • u
        • p
        • p
        • o
        • r
        • t
        • e
        • d
        • c
        • l
        • a
        • i
        • m
        • s
        • a
        • b
        • o
        • u
        • t
        • c
        • l
        • i
        • n
        • i
        • c
        • a
        • l
        • b
        • u
        • r
        • d
        • e
        • n
        • .

        Patient & Prescribing Data

        12 patients with pathologically confirmed angiosarcoma identified from 548 soft tissue sarcoma cases.

        First-line therapy was paclitaxel-based in 66.7% and anthracycline-based in 33.3% of advanced cases.

        Clinical Best Practices

        • edits

        Related Resources & Content

        Original Source(s)

        Angiosarcoma in a soft tissue sarcoma cohort: real-world patterns and outcomes

        • by Kübra Canaslan, Özge Yetginoğlu, Hasan Oğuz Çetinayak, Emine Burçin Tuna, Tuğba Yavuzşen

        • June 9, 2026

        Related Content

        First-line serplulimab plus chemotherapy versus chemotherapy alone in small-cell lung cancer patients with brain metastases: a multicenter, prospective cohort study

        This Week’s Biopharma News: Big Moves in Bispecifics

        Akeso’s PD-1/VEGF bispecific beats PD-1 plus chemo in lung cancer, Amgen wins EC approval for its DLL3-targeted T-cell engager, and Aragen scales Renaissance’s Fast Track anti-GD2 antibody

        • June 9, 2026

        • 5 min
        Association between tumor genomic mutations and the risk of PD-1 inhibitor-induced hypophysitis: a retrospective cohort study